News | July 06, 2022
Regeneron completes purchase of Sanofi's stake in Libtayo
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
It is a two dose vaccine to be administered intramuscularly at 28 days apart
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Subscribe To Our Newsletter & Stay Updated
